Umbilical cord mesenchymal stem cells combined with medicine for treating hyperglycemia and diabetic nephropathy

A technology of diabetic nephropathy and mesenchymal stem cells, which is applied in the field of preparation of drugs for the treatment of hyperglycemia and diabetic nephropathy, can solve problems such as liver damage, edema and weight of patients, and achieve the effect of improving kidney function and controlling blood sugar levels

Active Publication Date: 2018-07-27
华夏源(上海)生物科技有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs are mainly insulin sensitizers, but long-term use of these sensitizers can cause ed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Umbilical cord mesenchymal stem cells combined with medicine for treating hyperglycemia and diabetic nephropathy
  • Umbilical cord mesenchymal stem cells combined with medicine for treating hyperglycemia and diabetic nephropathy
  • Umbilical cord mesenchymal stem cells combined with medicine for treating hyperglycemia and diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Embodiment 1 Human umbilical cord mesenchymal stem cell culture and passage method

[0048] After primary culture, huMSCs (i.e. human umbilical cord mesenchymal stem cells) were placed in DMEM / F12 medium containing 10% FBS, 100U / ml penicillin and streptomycin; then, cultured at 37°C, 5% CO2 Routine culture and subculture in the box; the cells obtained from the subculture were digested with 0.25% trypsin, and the stably proliferating cells were collected.

[0049] will be 10 6 The collected human umbilical cord mesenchymal stem cells were suspended in 100ml PBS buffer solution containing 1% bovine serum albumin, and positive antibodies (CD90, CD105, CD73) and negative antibodies (CD45, CD34, CD11b) were detected by flow cytometry , CD19 and HLA-DR) expression. see results figure 1 , showing that the cultured human umbilical cord mesenchymal stem cells meet the standard of stem cells.

Embodiment 2

[0050] Embodiment 2, the preparation of Chinese medicine extract

[0051] Each Chinese medicine extract is prepared according to the following method:

[0052] Take ginseng, salvia miltiorrhiza, and astragalus, slice, filter, dry and grind into powder, pass through a 80-120 mesh sieve to obtain fine powder, and set aside.

[0053] Crush schisandra and Panax notoginseng, put them in a container, immerse in 6-16 times the volume concentration of 50-80% ethanol solution for 1-10 hours, heat and reflux extraction 3 times, each time for 1-6 hours, filter, and combine the filtrates , ethanol was distilled off under reduced pressure and concentrated to a concentrated solution with a relative density of 1.10-1.13 at 60°C for later use.

[0054] Atractylodes macrocephala was decocted and extracted three times with 12 times, 10 times and 8 times the amount of water respectively, each time for 2 hours, the three water extracts were combined, concentrated under reduced pressure to 1g medici

experiment example 3

[0055] Experimental Example 3 Effects of Chinese Medicine Extracts on the Growth of Human Umbilical Cord Mesenchymal Stem Cells and Glomerular Cells

[0056] Select huMSCs (human umbilical cord mesenchymal stem cells) and HMC (glomerular cells) in good growth state to divide 3×10 3 Each well was inoculated in a 96-well plate. After the cells adhered to the wall, different concentrations of Chinese herbal extracts were added for co-cultivation. The control group did not add Chinese herbal extracts, and the zero wells did not contain cells. Only 100 μL of culture solution was added, and each group was parallelized. Make 5 duplicate wells, add 10 μL CCK8 solution to each group after culturing for 4h, 24h, 48h, and 72h, incubate at 37°C for 4h, select 490nm wavelength to measure the absorbance (OD) value of each well. Effective concentration measured according to cck-8 results. The test results are shown in Figure 2 and Figure 3.

[0057] The test results show that the traditional

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of umbilical cord mesenchymal stem cells combined with a traditional Chinese medicine extract for preparing a medicine for treating hyperglycemia and diabetic nephropathy. In the application, the umbilical cord mesenchymal stem cells with the differentiative capacity and the potential for treating diabetes are combined with the traditional Chinese medicine extract capable of reducing blood glucose and improving a kidney state and with the inhibitory effect to kidney diseases caused by the diabetes, so that the medicine for treating the hyperglycemia and the diabetic nephropathy is prepared, thereby the blood glucose can be effectively controlled, and the kidney function is improved.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner 华夏源(上海)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products